INOVIO Pharmaceuticals, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual report; the filing does not provide a standalone Q4 income statement summary. Financial amounts below are U.S. dollars.
Business context
INOVIO is a clinical-stage biotechnology company developing DNA medicines delivered with its investigational CELLECTRA electroporation devices, primarily for HPV-related diseases, cancer, and infectious diseases. It had no approved products and generated no product-sales revenue. The company reported an accumulated deficit of $1.49 billion and expects ongoing losses while it develops its pipeline.
Financial results and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $10.3 million | $1.8 million |
| Research and development expense | $187.7 million | $249.2 million |
| General and administrative expense | $90.2 million | $53.8 million |
| Total operating expenses | $277.8 million | $303.0 million |
| Operating loss | $267.6 million | $301.2 million |
| Net loss | $279.8 million | $303.7 million |
| Basic and diluted net loss per share | $1.17 | $1.45 |
| Net cash used in operating activities | $216.2 million | $215.7 million |
- Revenue increased 478%, mainly from completion of the Department of Defense (DoD) device procurement contract. The DoD represented 94% of FY2022 revenue, versus 43% in FY2021, creating substantial customer concentration.
- R&D expense fell 25%, primarily reflecting lower INO-4800 manufacturing and outside-service costs, reduced device-development spending, and lower VGX-3100 costs. Grant reimbursements recorded as offsets to R&D expense also declined, to $24.5 million from $53.7 million.
- G&A expense rose 68%, reflecting litigation-related costs, legal expenses, and the former CEO’s separation costs. The securities settlement contributed $44.0 million of gross expense, offset by $30.0 million in insurance recoveries; the $14.0 million net amount was payable in stock.
- Cash and short-term investments totaled $253.0 million at year-end, down from $401.3 million; working capital was $218.4 million, down from $382.7 million. Operating cash use was broadly unchanged year over year.
- Investing activities provided $109.6 million, mainly due to the timing of investment sales and maturities; financing activities provided $81.8 million. INOVIO raised $83.0 million net under its at-the-market (ATM) offering in 2022 by issuing 34.4 million shares. The ATM had $167.4 million of stated capacity remaining at year-end.
- The 6.50% convertible senior notes mature in March 2024. After prior conversions, $16.4 million of principal remained; the balance-sheet carrying amount was $16.6 million. Contractual payments, including interest, were $18.0 million. The filing also reports $20.1 million of future operating-lease payments and $11.5 million of manufacturing commitments.
- Investment-value changes included a $7.8 million net unrealized loss on available-for-sale equity securities; management attributed unrealized losses on debt securities mainly to higher interest rates, not credit deterioration. Interest income increased to $4.8 million.
Material changes and pipeline developments
- INO-3107 for recurrent respiratory papillomatosis (RRP): The initial Phase 1/2 cohort showed a statistically significant median reduction of three surgeries in the year after treatment versus the year before; 16 of 21 participants had fewer surgeries. The filing also reports February 2023 preliminary second-cohort results: 10 of 11 participants had fewer surgeries, with a median decrease of three. These are preliminary clinical findings, not regulatory approval.
- VGX-3100 for cervical HSIL: REVEAL1 missed statistical significance for its primary endpoint in the intention-to-treat population, though it met the endpoint in the evaluable modified population. In March 2023, the company reported that REVEAL2 did not reach significance in its investigational biomarker-selected population but did in the all-participants population. The FDA had advised that REVEAL2 would be exploratory and would not support a filing for the biomarker-selected population; additional well-controlled trials may be needed. The combined REVEAL1/REVEAL2 analyses were post hoc and described as supportive, not a substitute for further regulatory evidence.
- COVID-19 vaccine INO-4800: INOVIO discontinued internally funded primary-vaccine and heterologous-booster development in 2022. It had no active company-run INO-4800 clinical trials; Advaccine continued its own development in China, and INO-4800 remained in the WHO Solidarity Trial Vaccines.
- Other programs: INOVIO and CEPI discontinued INO-4700 for MERS and INO-4500 for Lassa fever after the two-dose regimens did not meet CEPI’s selection criteria. A sponsored prostate-cancer combination involving INO-5151 was not advanced after sponsors judged clinical activity insufficient. INO-5401 GBM results were preliminary and compared favorably with historical survival benchmarks, not a controlled comparison.
Outlook, risks, and unusual items
- Management said year-end cash and short-term investments were sufficient for at least 12 months from the financial-statement issuance date, and projected cash runway into the first quarter of 2025 after cost reductions and discontinuation of internally funded INO-4800 work. The runway estimate assumes no additional capital raises; the company said further financing would be needed to complete clinical development and commercialize any approved products.
- A July 2022 restructuring reduced headcount by about 55 employees and ended agreements with about 86% of contractors. A January 2023 reduction eliminated about 24 more positions, with expected annual savings of $4.3 million and a one-time pre-tax charge of about $1.1 million. The 2023 action is subsequent to the reporting year.
- The securities class-action settlement was approved in January 2023: $30.0 million cash, paid by insurers, plus $14.0 million in company shares. INOVIO issued 7.0 million shares in February 2023 and expected a further share contribution valued at approximately $2.1 million after the appeal period or any appeal resolution. Derivative suits remained stayed; separate supplier-related litigation with VGXI and GeneOne was ongoing, with no trial dates set.
- Key risks include recurring losses and dependence on additional financing, clinical and regulatory uncertainty, reliance on a concentrated set of government and collaboration funding sources, manufacturing and single-source supplier constraints, competition, potential dilution, and litigation. The company also cited uncertainty around Chinese regulatory and political conditions and potential supply-chain effects.
- The company reported effective disclosure controls and internal control over financial reporting as of December 31, 2022. The auditor issued an unqualified opinion on the financial statements; its report identified accrual of clinical-trial expenses as a critical audit matter.
Most important facts for investors to verify
- Current cash, investment balances, quarterly operating cash burn, and whether management’s stated runway remains achievable without financing.
- Progress and regulatory feedback for INO-3107, including the design, endpoints, funding, and timing of any pivotal trial.
- What further trials or evidence the FDA requires for VGX-3100, and whether the company will fund or partner for them.
- DoD contract completion and the sustainability of revenue given that the DoD generated 94% of FY2022 revenue.
- Remaining ATM capacity, subsequent share issuance, convertible-note repayment or conversion terms, and the dilution implications of additional financing.
- Resolution and potential financial exposure from VGXI, GeneOne, and shareholder derivative litigation, as well as the final share contribution under the class-action settlement.